Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228559 · ClinicalTrials.gov registry record · Phase 1
A Study of Avoralstat In Participants With Diabetic Macular Edema
A Phase 1 study of Diabetic Macular Edema (DME), sponsored by BioCryst Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 8
- Study locations
NCT07228559: Recruiting Phase 1 study of Diabetic Macular Edema (DME), sponsored by BioCryst Pharmaceuticals.
NCT07228559 is a Phase 1 study of Diabetic Macular Edema (DME) that is actively recruiting participants, run by BioCryst Pharmaceuticals. The registered enrollment target is 9 participants, below the 361-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228559, a Phase 1 study of Diabetic Macular Edema (DME), is actively recruiting participants, sponsored by BioCryst Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
Conditions Studied
Interventions
- DRUG avoralstat
Study Locations (8)
New South Wales
- Investigative Site 1 - Sydney
- Investigative Site 2 - Sydney
- Investigative Site 3 - Sydney
Texas
- Investigative Site 7 - Katy
- Investigative Site 8 - The Woodlands
California
- Investigative Site 6 - Sacramento
South Australia
- Investigative Site 4 - Adelaide
Victoria
- Investigative Site 5 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT07228559 shows while recruiting
NCT07228559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 361-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetic Macular Edema (DME) appearing as the primary indexed condition, and to 1 intervention - of which avoralstat is the first listed.
NCT07228559 lists 8 locations in 5 states (New South Wales, Texas, California).
Frequently Asked Questions
What is clinical trial NCT07228559 about?
NCT07228559 is a clinical study titled "A Study of Avoralstat In Participants With Diabetic Macular Edema". The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
What is the current status of trial NCT07228559?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-10-02. Estimated completion is 2026-09.
What conditions does trial NCT07228559 study?
This clinical trial studies the following conditions: Diabetic Macular Edema (DME).
What interventions are being tested in trial NCT07228559?
The interventions under investigation include: avoralstat (DRUG).
Who is sponsoring clinical trial NCT07228559?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228559 being conducted?
This trial has 8 study locations across California, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema (DME)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228559's enrollment target sits among peer trials
9 9th of 8 the lowest of 8 other Diabetic Macular Edema (DME) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema (DME) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
COMPLETED · Phase 1
-
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
RECRUITING · Phase 4
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI